Clinical Trial Update: Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated lanreotide to prevent lymphorrhea after axillary dissection in breast cancer patients and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lanreotide (lanreotide)

Snippet

Sponsor: University Hospital, Limoges | Conditions: Lymphocele | Phase 3 | Status: COMPLETED